Lipid-based drug delivery systems have found widespread acceptance for development of drug products containing APIs posing developability challenges for formulators. This is evidenced by the significant numbers of FDA approved drug products that have been formulated using lipid-based formulations when a bioavailability-enhancing technology is required. This whitepaper covers:

• The lipid-based formulation classification system

• How Target Product Profile, technical limitations, and phase of development impact lipid-based drug delivery system choice
• The characteristics of each capsule shell technology